Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit 1,2 . However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood 3-5 . Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells 6, 7 . Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphasepromoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumourinfiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
. Although it has been reported that PD-L1 expression can be regulated at both transcriptional 9, 10 and post-translational levels 11, 12 , it remains unclear whether PD-L1 stability is regulated under physiological conditions such as during cell cycle progression. We found that PD-L1 protein abundance fluctuated during cell cycle progression in multiple human cancer cell lines, peaking in M and early G1 phases, followed by a sharp reduction in late G1 and S phases (Fig. 1a-d and Extended Data Fig. 1a-g ). Increased PD-L1 protein abundance was also observed in multiple mouse tumour-derived cell lines arrested in M phase by nocodazole or taxol 13 (Extended Data Fig. 1h -m).
Cyclin-dependent kinases play crucial roles in regulating the stability of cell cycle-related proteins during cell cycle progression 14, 15 . Therefore, we adopted a genetic method to ablate each major cyclin and found that ablating all three D-type cyclins (D1, D2 and D3), but not cyclin A (A1 and A2) or cyclin E (E1 and E2), strongly increased PD-L1 protein abundance in mouse embryonic fibroblasts (MEFs) ( Fig. 2a and Extended Data Fig. 2a-e) . Using MEFs lacking individual D-type cyclins, we observed that depletion of cyclin D1, and to a lesser extent cyclin D2 or D3, upregulated PD-L1 protein levels (Fig. 2b, c) . Conversely, reintroduction of cyclin D1, and to a lesser extent cyclin D2 or D3, suppressed PD-L1 protein abundance in triple knockout Ccnd1 −/− Ccnd2 −/− Ccnd3 −/− MEFs (Extended Data Fig. 2f ). In further support of a physiological role for cyclin D1 in negatively regulating PD-L1 protein level in vivo, mammary carcinomas arising in Ccnd1 −/− MMTV-Wnt1 or MMTVMyc mice displayed increased PD-L1 protein levels, as compared to tumours arising in Ccnd1 +/+ animals ( Fig. 2d and Extended Data Fig. 2g) .
Depletion of the cyclin D catalytic partner cyclin-dependent kinase 4 (CDK4), but not CDK6 16 nor the cyclin A and cyclin E binding-partner, CDK2 17 , also increased PD-L1 protein abundance in cells (Fig. 2e , f and Extended Data Fig. 2h-j) . Conversely, ectopic expression of wildtype CDK4, but not the kinase-dead N158F mutant, decreased PD-L1 levels (Extended Data Fig. 2k, l) . Furthermore, treatment of multiple cancer cell lines with two different selective inhibitors of CDK4/6 kinase, palbociclib or ribociclib 8 , upregulated PD-L1 protein abundance and stability even in RB1-deficient cells (Fig. 2g, h and Extended Data Fig. 2m-q) .
RB1 is frequently inactivated in human cancers 18, 19 . In agreement with previous reports 20 , 21 , we found that RB1-deficient cancer cells often displayed high levels of the cyclin D-CDK4/6 inhibitor, p16 (also known as CDKN2A). Consistent with the notion that cyclin D1-CDK4 kinase suppresses PD-L1 levels, we observed that upregulation of p16 correlated with increased PD-L1abundance (Extended Data  Fig. 2r ). Moreover, in RB1-proficient/p16-low cancer cell lines, higher PD-L1 levels correlated with relatively low CDK4 expression (Extended Data Fig. 2r ). In addition, ectopic expression of p16 in RB1-proficient/ p16-low cell lines (MCF7 and T47D) or an RB1-deficient/p16-low cell line (HLF) increased PD-L1 protein abundance (Extended Data Fig. 2s-u) , whereas depletion of p16 in RB1-deficient/p16-high cell lines (MDA-MB-436, BT549, and HCC1937) had the opposite effect (Extended Data Fig. 2v-x) , further documenting an inverse correlation between CDK4 activity and PD-L1 expression.
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To extend these observations to an in vivo setting, we treated transgenic MMTV-Erbb2 mice bearing autochthonous breast cancers, or mice carrying allografts of murine MC38 or B16-F10 cancer cell lines with palbociclib, and monitored PD-L1 levels. Inhibition of CDK4/6 led a significant upregulation of PD-L1 in all these cancer models, which was accompanied by a reduction in the number of infiltrating CD3 + tumour-infiltrating T lymphocytes (TILs) (Fig. 2i-k and Extended Data Fig. 3a-c) . We also observed that palbociclib treatment significantly increased PD-L1 protein levels in various organs of normal mice (Extended Data Fig. 3d-h ). Collectively, these results demonstrate that cyclin D-CDK4 kinase plays a rate-limiting role in regulating PD-L1 levels in vivo.
To understand how cyclin D-CDK4 regulates PD-L1 levels, we first determined that treatment of cells with proteasome inhibitor MG132, or with cullin-based ubiquitin E3 ligase inhibitor MLN4924 22 increased PD-L1 protein levels (Fig. 3a) . To identify which cullin family E3 ligase(s) regulates PD-L1, we screened the potential interaction of PD-L1 with each cullin family protein and found that cullin 3, and to a lesser extent cullin 1, interacted with PD-L1 in cells ( Fig. 3b and Extended Data Fig. 4a, b) . These results indicate that in addition to cullin 1/β-TRCP (β-transducin repeat containing E3 ubiquitin protein ligase) 11 , the cullin 3-based E3 ligase(s) might play a role in regulating PD-L1 stability. Consistent with this notion, depletion of cullin 3 increased the protein abundance of endogenous PD-L1 (Extended Data Fig. 4c ).
Cullin 3-based E3 ubiquitin ligases recognize their downstream substrates through substrate-recruiting adaptor proteins 23 . We found that SPOP, but not the other adaptor proteins we examined, interacted with PD-L1 in cells (Fig. 3c, d ). We further determined that deletion of the C-tail, or the last eight amino acids of PD-L1 (283-290), disrupted binding of PD-L1 to SPOP, and rendered PD-L1 resistant to SPOPmeditated poly-ubiquitination (Extended Data Fig. 4d-h ), indicating that the 283-290 region of PD-L1 might represent the potential binding motif for SPOP. Notably, a cancer-derived PD-L1 mutant containing a T290M mutation located within the SPOP-binding motif (cBioPortal) also lost its ability to interact with SPOP and became more stable through decreased SPOP-mediated poly-ubiquitination and degradation (Extended Data Fig. 4i-l) . Furthermore, depleting SPOP or −/− MEFs (e), MDA-MB-231 cells with CDK4 knockdown using shRNAs targeting CDK4 (shCDK4 #1 and shCDK4 #2) (f), or multiple breast cancer cell lines treated with palbociclib (0.5 μM, 1 μM) for 48 h (g, h). i, Representative immunofluorescence staining of PD-L1 and CD3 in mammary tumours induced by MMTV-Erbb2 and in mice treated with vehicle or palbociclib. Scale bars, 50 μm. j, The CD3 + TILs were quantified in tumours from mice treated with vehicle or palbociclib. k, FACS analysis of PD-L1 or CD3
+ TILs from MC38-implanted tumours; tumour-bearing mice were treated with vehicle or palbociclib for 7 days. Vehicle, n = 4 mice (i, j) or 7 mice (k); palbociclib, n = 4 mice (i, j) or 7 mice (k). Data are mean ± s.d. **P < 0.01, ***P < 0.001, two-tailed t-test.
deleting its substrate-interacting MATH domain increased and stabilized PD-L1 in cells (Fig. 3e, f and Extended Data Fig. 5a-m) . However, depleting known SPOP substrates including AR, ERG, TRIM24 or DEK in wild-type SPOP or SPOP −/− human tumour cell lines did not lead to obvious changes in PD-L1 levels (Extended Data Fig. 5n-u) , arguing against the possibility of secondary effects for the observed elevation of PD-L1 after SPOP depletion.
SPOP mutations occur in 10-15% of human prostate cancers, and are largely clustered within the MATH domain 24, 25 (Extended Data Fig. 6a ). Notably, these cancer-derived SPOP mutants failed to promote PD-L1 degradation owing to their deficiency in binding to PD-L1, which leads to a failure in the promotion of PD-L1 poly-ubiquitination (Fig. 3g-i and Extended Data Fig. 6b, c) . This behaviour resembles the elongin C-encoding ELOC hotspot mutants in clear cell renal carcinoma that result in deficiencies in the ability of cullin 2-elongin B/C-VHL E3 ligase complex to promote HIF-1α degradation 26 . We also observed that in human tumours mutations in the PD-L1 C-tail (degron) are mutually exclusive with mutations in the substrate-interacting MATH domain of SPOP (Extended Data Fig. 6d, e) .
To further explore the effect of SPOP mutations on tumorigenesis, we generated tumour cell lines expressing wild-type SPOP or cancerderived SPOP mutants. We found that cells expressing mutant SPOP displayed increased levels of endogenous PD-L1 protein, as compared to cells expressing wild-type SPOP (Fig. 3j and Extended Data Fig. 6f-j) . Upon inoculation into immunoproficient mice, the growth of implanted tumours expressing the cancer-derived SPOP(F102C) MEFs (e), SPOP-knockout human C4-2 cells (using three short guide RNAs (sgRNAs) targeting SPOP (sgSPOP 1, 2 and 3) were used along with a negative control (sgControl)) (f), or C4-2 cells stably expressing wild-type SPOP and indicated mutants fused with a haemagglutinin tag (HA-SPOP, F102C and W131G) (g). h, Immunoblot analysis of immunoprecipitates and WCL derived from HEK293T cells transfected with HA-PD-L1 and constructs containing wild-type and mutant Flag-tagged SPOP (Flag-SPOP) and treated with 30 μM MG132 for 6 h. i, Immunoblot analysis of immunoprecipitates and WCL from Ni-NTA pull-down products derived from PC3 cells transfected and treated as in h but with the additional transfection of a His-tagged ubiquitin construct (His-ubiquitin). j-l, FACS analysis for PD-L1 (j) or CD3 + T-cell population (k) in B16-F10-implanted tumours ectopically expressing wild-type SPOP or the F102C mutant (n = 6 mice each group). Tumour weights were recorded after euthanization of animals (l) (n = 5 mice each group). m, Representative images of PD-L1 and CD8 immunohistochemistry staining in wild-type or mutant SPOP primary human prostate cancer samples. Scales bar, 400 μm (top) or 100 μm (bottom). n, o, Quantification of immunohistochemical analysis for PD-L1 (n) and CD8 + T cells (o) in SPOP wild-type versus mutant human prostate tumour specimens. n = 15 for mutant SPOP, n = 82 for wild-type SPOP. j-l, n, Data are mean ± s.d. We next investigated whether loss-of-function SPOP mutations regulate PD-L1 levels or TILs in primary human prostate cancers. To this end, we identified 15 mutant SPOP and 82 wild-type SPOP tumours through large-scale sequencing as described 27, 28 . Immunohistochemistry staining results revealed that approximately 80% of mutant SPOP tumours exhibited strong PD-L1 staining. By contrast, only approximately 10% of wild-type SPOP tumours exhibited strong staining for PD-L1, whereas 70% of wild-type SPOP cases displayed weak or no PD-L1 staining (Fig. 3m , n and Extended Data Fig. 7a-d) . Moreover, the numbers of CD8 + TILs were reduced in samples harbouring SPOP mutations, as compared to wild-type SPOP tumours ( Fig. 3o and Extended Data Fig. 7e-h ). These results indicate that SPOP-deficiency correlates with increased PD-L1 protein abundance and decreased numbers of TILs in primary human prostate cancers.
We found that SPOP protein abundance fluctuated during the cell cycle and displayed an inverse correlation with PD-L1 protein levels (Figs 1a, 4a). Depleting SPOP resulted in stabilization of PD-L1 across the cell cycle ( Fig. 4a and Extended Data Fig. 8a ). We noted that the APC/C (anaphase-promoting complex, also known as cyclosome) E3 ligase adaptor protein FZR1 (also known as CDC20 homologue 1, CDH1) displayed an inverse correlation with SPOP protein levels during the cell cycle (Figs 1a, c, 4a). Furthermore, depletion of FZR1, but not CDC20, increased SPOP protein abundance, which was accompanied by a simultaneous reduction in PD-L1 protein levels (Extended Data Fig. 8b , c). Consistent with these results, we detected a physical interaction between the endo genous SPOP and FZR1 proteins ( Fig. 4b and Extended Data Fig. 8d , e), and identified an evolutionarily conserved destruction-box (D-box) motif (RXXLXXXXN) 29 in SPOP (Extended Data Fig. 8f ). Deleting the D-box motif in SPOP disrupted its binding to FZR1 and rendered SPOP resistant to FZR1-mediated poly-ubiquitination and degradation (Fig. 4c, d and Extended Data Fig. 8g-i) . Moreover, depletion of FZR1 led to SPOP stabilization, which subsequently resulted in a reduction in PD-L1 protein levels during cell cycle progression (Fig. 4e) . Taken together, these results indicate that FZR1 is a physiologically important upstream E3 ligase responsible for negatively regulating SPOP protein stability.
To determine how the cyclin D-CDK4 kinase affects this mechanism, we established that cyclin D1-CDK4 directly phosphorylates SPOP at Ser6 (p-Ser6), but not Ser222, the only two conserved serine-proline motifs in SPOP (Fig. 4f and Extended Data Fig. 9a-d) . Treatment of cells with palbociclib reduced the phosphorylation of SPOP in cells (Extended Data Fig. 9e ). We observed that 14-3-3γ protein physically interacted with SPOP in a p-Ser6-dependent manner and disrupted the interaction of SPOP with FZR1 in cells (Fig. 4g, h and Extended Data Fig. 9f-h ). Inhibition of SPOP-p-Ser6 decreased the interaction of SPOP with 14-3-3γ and increased its binding to FZR1, leading to increased SPOP poly-ubiquitination ( Fig. 4i and Extended Data Fig. 9i-p) . Consequently, palbociclib treatment decreased SPOP protein abundance and increased PD-L1 levels in wild-type SPOP, but not in SPOP-deficient cells (Fig. 4j) . Moreover, depletion of 14-3-3γ markedly upregulated PD-L1 levels and stabilized PD-L1 during cell cycle progression (Extended Data Fig. 9q-t) . Recent clinical studies revealed that the success of PD1-PD-L1 blockade correlates with PD-L1 expression levels in tumour cells 6, 7 . Given our observation that inhibition of CDK4/6 increased PD-L1 levels, we hypothesized that inhibitors of CDK4/6 kinases might synergize with anti-PD-1-PD-L1 therapy to elicit an enhanced therapeutic efficacy. Indeed, we observed that treatment of immunoproficient mice bearing CT26 tumours with palbociclib plus an anti-PD-1 antibody markedly retarded tumour progression and resulted in 8 complete responses out of 12 treated mice ( Fig. 4k and Extended Data Fig. 10a ). Moreover, combining CDK4/6 inhibitor with anti-PD-1 therapy resulted in a significant improvement in overall survival compared with either treatment alone (Fig. 4l) . Similar results were obtained using mice bearing tumours derived from mouse tumour MC38 cells. (Extended Data Fig. 10b, c) . As expected from our earlier observations, treatment of tumour-bearing mice with palbociclib decreased the absolute numbers of TILs, including CD3
+ and IFNγ + cells. Notably, the addition of anti-PD-1 antibody to palbociclib treatment restored essentially normal numbers of TILs (Extended Data Fig. 10d-j) .
A recent study revealed that another inhibitor of CDK4/6, abemaciclib, increased the immunogenicity of cancer cells via an RB1-dependent mechanism, first by activating tumour cell expression of endogenous retroviral elements, and then by stimulating the production of type III interferons and antigen presentation by tumour cells 30 . Together with our demonstration that cyclin D-CDK4 regulates PD-L1 stability through cullin 3-SPOP (Extended Data Fig. 10k ), these studies provide a complementary molecular rationale for combining CDK4/6 inhibitor treatment with immunotherapy targeting the PD-1-PD-L1 interaction to enhance tumour regression.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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Cell culture, transfections and viral infections. HEK293T, HEK293, HeLa, MDA-MB-231, MCF7, Hs578T cells and MEFs (wild-type, Ccnd1
and Spop −/− MEFs (a gift from N. Mitsiadesa)) were cultured in DMEM medium supplemented with 10% FBS (Gibco), 100 U of penicillin and 100 μg ml −1 streptomycin (Gibco). HLF, HepG2, Huh1 and Huh7 were cultured in RPMI medium supplemented with 10% FBS. MDA-MB-231 wild-type PD-L1 and PD-L1-knockout cells were a gift from M.-C. Hung. BT549, T47D, ZR75-1, HCC1954, HCC1937, MDA-MB436, MDA-MB468 and SKBR3 cells were from the A. Toker laboratory, and were cultured in RPMI medium or McCoy's 5A (Corning) medium supplemented with 10% FBS. PC3, DU145, 22RV1, LNCaP and C4-2 were gifts from the P. P. Pandolfi group, and cultured in RPMI medium (Corning) with 10% FBS. The mouse tumour-derived MC38 cell line was a gift from A. Sharpe. Mouse tumour-derived CT26, 4T1 and B16-F10 cell lines were routinely cultured in the laboratory of G.J.F. in DMEM medium supplemented with 10% FBS (Gibco), 100 U of penicillin and 100 μg ml −1 streptomycin (Gibco). All cell lines were routinely tested for mycoplasma contamination and found to be negative.
Cells with 80% confluence were transfected using Lipofectamine Plus reagents in Opti-MEM medium (Invitrogen). 293FT cells were used for packaging of lentiviral and retroviral cDNA-expressing viruses; subsequent infection of various cell lines were performed. In brief, medium with secreted viruses was collected twice at 48 h and 72 h after transfection. After filtering through 0.45 μm filters, viruses were used to infect cells in the presence of 4 μg ml −1 polybrene (SigmaAldrich). Cells were split 48 h after infection and selected using hygromycin B (200 μg ml ) for three days. Cells were collected and lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP40) supplemented with protease inhibitors (Roche) and phosphatase inhibitors (Calbiochem) for immunoblot analysis. Reagents. Nocodazole (M1404) and taxol (T7402) were purchased from Sigma, thymidine (50-89-5) and cycloheximide (66-81-9) from Acros Organics, palbociclib (PD0332991, S1116) and ribociclib (LEE011, S7440) from Selleckchem and Abmole, and MG132 (BML-PI102-0005) from Enzo Life Science. MLN4924 was a gift from W. Kaelin. Plasmids. MYC-tagged cullin 1, cullin 2, cullin 3, cullin 4A, cullin 4B and cullin 5; Flag-tagged wild-type SPOP and mutants (Y87C, F102C and W131G); delta MATH; delta BTB; HA-tagged wild-type SPOP (pLenti-HA-SPOP) and mutants (Y87C, F102C and W131G); pGEX-4T-1-SPOP; Flag-Keap1; Flag-Cop1; shScramble; shCullin 3; shSPOP; and His-ubiquitin constructs have been described previously 31 . shAR, shERG, shTrim24, shDEK and sgSPOP constructs (sgSPOP 1: CCACTCGACATTTCTGCCGG; sgSPOP 2: TAACTTTAGCTTTTGCCGGG; sgSPOP 3: GCTGTCCAAAGAGTGAAGTT) have been described previously 31 . sgControl (CGCTTCCGCGGCCCGTTCAA) was a gift from W. Kaelin. MYCcullin 7 construct was from J. A. DeCaprio. KLHL2 and KLHL3 constructs were gifts from S. Uchida. KLHL12 and KLHL37 constructs were purchased from Addgene. KLHL20 construct was from R.-H. Chen. The construct of HA-PD-L1 (HA tag in the N terminus of PD-L1) was provided by M.-C. Hung. HA-FZR1, HA-CDC20, shFZR1, shCDC20 and HA-14-3-3 isoform constructs were described previously 32, 33 . Wild-type pCMV-CDK4, pCMV-CDK4 N158F and shCCND3 were described previously 34, 35 . pBabe-p16 was a gift from the laboratory of C. J. Sherr. pLKO-shCDK4 (78153 and 78154) and pMLP-shCDK6 (73552 and 73553) were purchased from Addgene. pLKO-sh14-3-3γ (TRCN0000078160, TRCN0000078161, TRCN0000078162), pLKO-shp16 (TRCN0000039748, TRCN0000039751, TRCN0000039782) and pLKO-shCD8a (TRCN0000057583, TRCN0000057587) were purchased from Open Biosystems. pcDNA3-PD-L1, pCMV-GST-PD-L1-tail (cytoplasmic amino acids), HA-PD-L1-ΔC-tail, HA-PD-L1-Δ283-290, HA-PD-L1-S283A, HA-PD-L1-S285A, HA-PD-L1-T290M, wild-type pLenti-PD-L1, pLenti-PD-L1-Δ283-290, pLenti-PD-L1 T290M, pET-28a-His-SPOP (wild-type, S6A, S222A and S6A/S222A mutants), Flag-SPOP with ΔD-box (ΔRXXL), pLenti-HA-Myc (wild-type and T58A/S62A mutant), pLenti-HA-cyclin D1, pLenti-HA-cyclin D2, pLenti-HA-cyclin D3, Flag-SPOP S6A, HA-tagged CDK2, CDK4 and CDK6 were generated in this study. Antibodies. Anti-PD-L1 (E1L3N) rabbit monoclonal antibody (13684), antipS10-H3 (3377), anti-p-S780-Rb (8180), anti-pS807/S811-Rb (8516), anti-Rb (9309), anti-cyclin D1 (2978), anti-cyclin D2 (3741), anti-CDK6 (3136), anti-cullin 3 (2759), anti-GST (2625), rabbit polyclonal anti-Myc-Tag antibody (2278) and mouse monoclonal anti-Myc-Tag (2276) antibodies were purchased from Cell Signaling Technology. Mouse PD-L1 antibody (MAB90781-100) was purchased from R&D Systems. Anti-mouse PD-L1 for immunoblotting (clone 298B.8E2), anti-mouse PD-L1 (clone 298B.3G6) for immunohistochemistry, and anti-human PD-L1 for immunoprecipitation (clone 29E.12B1) were generated in the laboratory of G.J.F. Anti-CDK4 (MS-616-P1) was purchased from Thermo Fisher Scientific. Anti-SPOP (16750-1-AP) was purchased from Proteintech. Anti-cyclin A (sc-751), anti-cyclin B (sc-245), anti-cyclin E (SC-247), anti-cyclin D3 (sc-182), anti-FZR1 (sc56312), anti-CDC20 (sc-8358), anti-CDC20 (sc-13162), anti-PLK1 (sc-17783), anti-TRIM24 (TIF1α, SC-271266), anti-HA (sc-805, Y-11), anti-PD-L1 (sc-50298) and anti-GST (sc-459) were obtained from Santa Cruz. Anti-GFP (8371-2) was purchased from Clontech. Anti-Flag (F-2425), anti-Flag (F-3165, clone M2), anti-vinculin (V9131), anti-Flag agarose beads (A-2220), anti-HA agarose beads (A-2095), peroxidase-conjugated anti-mouse secondary antibody (A-4416) and peroxidase-conjugated anti-rabbit secondary antibody (A-4914) were purchased from Sigma. Anti-HA (MMS-101P) was obtained from BioLegend. Immunoblot and immunoprecipitation analyses. Cells were lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40) supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbiochem). Protein concentrations were measured using a Beckman Coulter DU-800 spectrophotometer using the Bio-Rad protein assay reagent. Equal amounts of protein were resolved by SDS-PAGE and immunoblotted with indicated antibodies. For immunoprecipitations analysis, 1,000 μg total cell lysates were incubated with the primary antibody-conjugated beads for 4 h at 4 °C. The recovered immunocomplexes were washed four times with NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40) before being resolved by SDS-PAGE and immunoblotted with indicated antibodies. Immunohistochemistry for cell pellets, xenografted tumours or human prostate tumour specimens. The cultured cells (MDA-MB-231 wild-type PD-L1 and PD-L1-knockout cells; HBP-ALL shScramble and shCD8 cells; KE37 shScramble and shCD8 cells) were washed and fixed in 4% paraformaldehyde for 20 min. Cell pellets or xenografted (MDA-MB-231 wild-type PD-L1 and PD-L1 knockout) tumours were embedded into tissue freezing medium (TFM) and frozen. Cryostat sections (10 μm) were placed on Superfrost Plus Stain slides, and samples were then permeabilized in 0.1% Triton X-100/PBS for 10 min. For immunohisto chemistry analysis, we used UltraSensitive SP (mouse) IHC Kit (KIT-9701, Fuzhou Maixin Biotech) or Vectastain Elite ABC reagent (DAB Peroxidase Substrate kit, Vector Laboratories, SK-4100) following the manufacturer's instructions with minor modification. The sections were incubated with 3% H 2 O 2 for 15 min at room temperature to block endogenous peroxidase activity. After incubating in normal goat serum for 1 h to block non-specific binding of IgG, sections were treated with primary antibody (PD-L1, 298B.3G6, 18 μg ml −1 ; CD8α, sc-53212, clone C8/144B, dilution 1:40) at 4 °C overnight. Sections were then incubated for 30 min with biotinylated goat-anti-mouse IgG secondary antibodies (Fuzhou Maixin Biotech), followed by incubation with streptavidin-conjugated HRP (Fuzhou Maixin Biotech), and were developed with 3,3′-diaminobenzidine(DAB-2031, Fuzhou Maixin Biotech). Images were taken using an Olympus microscopic camera and matched software.
The prostate tumour specimens were obtained from Shanghai Changhai Hospital. Usage of these specimens was approved by the Institute Review Board of Shanghai Changhai Hospital. For immunohistochemistry, the paraformaldehyde-fixed paraffin-embedded prostate tumour samples were deparaffinized in xylene (three times for 10 min), rehydrated through a series of graded alcohols (100%, 95%, 85%, and 75%) to water. Samples were then subjected to heat-mediated antigen retrieval at 95 °C for 20 min. The subsequent staining steps were the same as those described above.
The expression level of PD-L1 in prostate cancer tumour samples was determined according to the intensity of the staining as 0, negative; 1, weak expression; 2, intermediate expression and 3, strong expression. The numbers of intraepithelial CD8 + TILs were counted as previously described 36 . In brief, three independent areas with the most abundant infiltration were selected under a microscopic field at 200× magnification (0.0625 mm 2 ). The number of intraepithelial CD8 + TILs was counted manually and calculated as cells per mm 2 . The Mann-Whitney test was used to compare the difference in PD-L1 expression between wild-type and mutated SPOP cases. A Student's t-test was used to determine P values of the difference in CD8
+ TILs between wild-type and mutant SPOP cases. P < 0.05 was considered significant. In vitro cyclin D-CDK4 kinase assays. Kinase assays were performed in a final volume of 30 μl of a kinase buffer as described previously 37 : 50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM dithiothreitol (DTT), 1 mM EGTA, 0.1 mM NaF, containing 10 μM ATP and 0.4 mCi [γ- 2 μg of His-SPOP, His-SPOP-S6A, His-SPOP-S222A, or His-SPOP-S6A/S222A mutant proteins immobilized on Ni-NTA beads were used as kinase substrates. 0.1 μg of Rb C-terminal recombinant protein (SC-4112, Santa Cruz) was used as a positive control for kinase assays. 2 μg of BSA was used as a negative control. After 60 min incubation at 30 °C, proteins were denatured, resolved on SDS-PAGE, transferred to nitrocellulose membranes and exposed to X-ray films. Kinase assays of endogenous CDK4-cyclin D1 from mice organs. The endogenous CDK4 was immunoprecipitated using 6 μg of anti-CDK4 antibody (Santa Cruz, sc-23896 AC) from 2.5 mg of lysates (buffer: 20 mM Tris-HCl pH 8.0, 0.1 M KCl, 5 mM MgCl 2 , 10% glycerol, 0.1% Tween-20, 0.1% NP40) of livers or brains isolated from C57B/L6 mice. The association of cyclin D1 with CDK4 was confirmed by immunoblotting with an anti-cyclin D1 antibody (Abcam, ab134175). The immunopurified endogenous cyclin D1-CDK4 was used as kinase, and 0.5 μg of Rb C-terminal recombinant protein (SC-4112) was used as the kinase substrate. In vivo ubiquitination assays. PC3 or HeLa cells with 80% confluence were transfected with His-ubiquitin and the indicated constructs. Thirty-six hours after transfection, cells were treated with 30 μM MG132 for 6 h and lysed in buffer A (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , and 10 mM imidazole pH 8.0). After sonication, the lysates were incubated with Ni-NTA beads (QIAGEN) for 3 h at room temperature. Subsequently, the His pull-down products were washed twice with buffer A, twice with buffer A/TI (1 volume buffer A and 3 volumes buffer TI), and once with buffer TI (25 mM Tris-HCl and 20 mM imidazole pH 6.8).
The pull-down proteins were resolved by SDS-PAGE for immunoblotting. Protein half-life assays. Cells were transfected or treated under indicated conditions. For half-life studies, cycloheximide (20 μg ml −1 , Sigma) was added to the medium. At indicated time points thereafter, cells were collected and protein abundance was measured by immunoblot analysis. Cell synchronization and FACS analyses. Cells synchronized with nocodazole arrest and double thymidine treatment as described previously 38 were collected at the indicated time points and stained with propidium iodide (Roche) according to the manufacturer's instructions. Cells were fixed by 70% ethanol at −20 °C overnight and washed three times using cold PBS. The samples were digested with RNase for 30 min at 37 °C and stained with propidium iodide (Roche) according to the manufacturer's instructions. Stained cells were sorted with BD FACSCanto II Flow Cytometer. The results were analysed by ModFit LT 4.1 and FSC express 5 softwares. BrdU/PI labelling and FACS analyses. Cells were incubated with or without BrdU (75 μM, Sigma) containing medium for 1 h. Cells were collected and washed once with cold PBS for centrifugation for 5 min at 270g. Cells were re-suspended in 200 μl cold PBS and 5 ml of cold 90% ethanol was added for fixation overnight. After centrifugation for 5 min at 270g, cells were washed once using 5 ml PBS and 0.5 ml 2 N HCl-0.5% Triton X-100 was added for 30 min at room temperature. After adding in 5 ml PBS, samples were centrifuged for 5 min at 270g and re-suspended in 1 ml Na 2 B 4 O 7 (pH 8.5). Samples were re-suspended in 200 μl anti-BrdU diluted (1:40) in PBS with 0.5% Tween 20 and 1% BSA and were incubated 30 min at room temperature. After adding 5 ml 20 mM HEPES-PBS (pH 7.4) with 0.5% Tween 20, samples were centrifuged for 5 min at 270g and re-suspended in 0.5 ml PBS with propidium iodide (PI, 5 μg ml , Roche). After incubating 30 min at room temperature, samples were transfered into FACS tubes and analysed by flow cytometry. Real-time RT-PCR analyses. Total RNAs were extracted using the QIAGEN RNeasy mini kit, and reverse transcription reactions were performed using the ABI Taqman Reverse Transcription Reagents (N808-0234). After mixing the generated cDNA templates with primers, probes and ABI Taqman Fast Universal PCR Master Mix (4352042), reactions were performed with the ABI-7500 Fast Real-time PCR system and SYBR green qPCR Mastermix (600828) from Agilent Technologies Stratagene. The following primers were used human GAPDH: forward, 5′-GGAGCGAGATCCCTCCAAAAT-3′, reverse, 5′-GGCTGTTGTCATACTTCTCATGG-3′; mouse Gapdh: forward, 5′-AGGTCGGTGTGAACGGATTTG-3′, reverse, 5′-GGGGTCGTTGATGGCA ACA-3′; human PD-L1 (also known as CD274): forward, 5′-TGGCATTTGCTG AACGCATTT-3′, reverse, 5′-TGCAGCCAGGTCTAATTGTTTT-3′; mouse PD-L1 (also known as Cd274): forward, 5′-GCTCCAAAGGACTTGTACGTG-3′, reverse, 5′-TGATCTGAAGGGCAGCATTTC-3′. Generation of Ccnd-deficient MEFs. Ccnd1 . MMTV-Erbb2 female mice (from the Jackson Laboratory), bred into a mixed C57BL/6 and 129Sv background, were treated with palbociclib or vehicle only for 6 weeks after detection of palpable tumours. Mice with tumours were pooled and randomly divided into two groups. Palbociclib was administered daily by gastric gavage (150 mg kg −1 of body weight); every two weeks the daily dose was lowered to 100 mg kg −1 for 2-3 days. Control mice were treated with vehicle (10% 0.1 N HCl, 10% Cremaphor EL, 20% PEG300, 60% 50 mM citrate buffer pH 4.5) 10 ml kg −1 by gastric gavage. After 6 weeks, tumours were collected and snapfrozen in optimal cutting temperature compound 40 . Treatment of wild-type mice with palbociclib. 6-week-old C57BL/6 female mice (from the Jackson Laboratory) were randomly divided into two groups. Mice were treated daily with palbociclib (150 mg kg −1 , by gastric gavage) or vehicle only for 7 days. Subsequently, organs were collected and analysed by immunoblotting. Mouse tumour implantation. Cells (1 × 10 5 B16-F10, or 2 × 10 5 MC38) were injected subcutaneously into 6-week-old C57BL/6 female mice (from the Jackson Laboratory). Starting one week later, mice were pooled and randomly divided into two groups. Mice were treated daily with palbociclib (150 mg kg −1 , by gastric gavage) or vehicle only, for 7 days. Subsequently, tumours were collected and analysed by FACS or immunoblotting.
Cells (1 × 10 5 B16-F10) stably expressing wild-type SPOP or F102C mutant were injected subcutaneously into 6-week-old C57BL/6 female mice (from the Jackson Laboratory). Three days after tumour cells were injected, control and anti-PD-L1 antibody (clone 10F.9G2) treatments were conducted by intraperitoneal injection (200 μg per mouse in 200 μl HBSS saline buffer) every three days for a total of three injections. Subsequently, tumours were collected and analysed by FACS.
Cells (1 × 10 5 B16-F10) stably expressing wild-type SPOP or F102C mutant were injected subcutaneously into 6-week-old Tcra −/− female mice (from the Jackson Laboratory). After 10 days, tumours were collected and analysed by FACS. Immunofluorescence staining of cells or tumour tissues. MDA-MB-231 PD-L1 wild-type and knockout cells were seeded in chambers (154534, Thermo Fisher Scientific). Cells were fixed with 4% paraformaldehyde for 20 min, followed with 0.1% Triton X-100 in PBS for 10 min. Cells were pre-blocked with 2% BSA/PBS for 45 min, then incubated with primary antibodies against PD-L1 (PD-L1, 298B.3G6, 1:200), for 2.5 h at room temperature and followed with secondary anti-mouse antibodies conjugated with Alexa-Fluor-568 (Invitrogen, 1:250). Hoechst (Life Technology, 1:10,000) was used to stain nuclei.
TFM-embedded 10 μm-thick tumour tissue sections were fixed with 2% paraformaldehyde-PBS for 30 min, and permeabilized in 0.1% Triton X-100/PBS for 10 min. Tumour tissue sections were pre-blocked with 2% BSA/PBS for 45 min, then incubated with primary antibodies against PD-L1 (1:200), CD3 (Abcam, 1:250) for 2.5 h at room temperature. Sections were then incubated with secondary anti-mouse antibodies conjugated with Alexa-Fluor-568 (Invitrogen, 1:250) and anti-rabbit antibodies conjugated with Alexa-Fluor-488 (Invitrogen, 1:250). Hoechst (Life Technology, 1:10,000) was used to stain the nuclei. Tumour tissues were mounted with fluoromount-G (SouthernBiotech) at 4 °C overnight. Tissue sections were examined with fluorescent microscope under a 20× objective lens. CD3
+ cell numbers were counted in an area of 3.67 × 10 5 μm 2 . Single-cell generation from tumour tissue and flow cytometry analysis. Tumour tissues were minced and digested with 5 ml of 2 mg ml −1 collagenase (Sigma) in DMEM for 1 h at 37 °C. Cells were then collected by centrifugation and filtered through a 70-μm strainer in DMEM. Cell pellets were suspended and lysed in red blood cell lysis buffer for 5 min. The cells were then filtered through a 40-μm strainer in 1× PBS with 2% BSA. A volume equivalent to 10 6 cells were incubated with antibodies against PD-L1 (564715, BD Biosciences, 1:100) conjugated with allophycocyanin (APC), antibodies against CD3 (Biolegend, 1:100) conjugated with APC or a corresponding isotype IgG1 control at room temperature for 30 min. Cells were washed with PBS and 2% BSA and analysed by flow cytometry. In vivo experimental therapy in MC38 and CT26 mice tumour models. Animal studies were approved by Dana-Farber Cancer Institute Institutional Animal Care and Use Committee (IACUC; protocol number 04-047), and performed in accordance with guidelines established by NIH Guide for the care and use of laboratory animals. MC38 or CT26 tumours were established by subcutaneously injecting 1 × 10 5 MC38 or CT26 tumour cells in 100 μl HBSS into the right flank of 6-weekold C57BL/6 (for MC38) or BALB/c (for CT26) female mice (Jackson Laboratory). Tumour sizes were measured every three days by caliper after implantation and tumour volume was calculated by length × width 2 × 0.5. Seven days after tumour cells were injected, animals were pooled and randomly divided into four groups with comparable average tumour size. Laboratory members who measured the mice were blinded to the treatment groups. Mice were grouped into control antibody treatment, anti-PD-1 antibody treatment (clone 29F.1A12), CDK4/6 inhibitor treatment, and anti-PD-1 antibody plus CDK4/6 inhibitor treatment. As illustrated in Extended Data Fig. 10a , control and anti-PD-1 antibody treatments were conducted by intraperitoneal injection (200 μg per mouse in 200 μl HBSS saline buffer) every three days for a total of 8 injections. The CDK4/6 inhibitor treatment was given by oral gavage once a day with a dosage of 100 mg kg −1 for three weeks with
Letter reSeArCH a break every week for one day. For survival studies, animals were monitored for tumour volumes every three days for 120 days (MC38) or 57 days (CT26) after initial treatment, until tumour volume exceeded 2,000 mm 3 (MC38) or 1,500 mm 3 (CT26), or until tumours had an ulcer with a diameter of 1 cm. Statistical analysis was conducted using the GraphPad Prism software (GraphPad Software). Kaplan-Meier curves and corresponding Gehan-Breslow-Wilcoxon tests were used to evaluate the statistical differences between groups in survival studies. P < 0.05 was considered significant. T cell analysis for MC38-implanted tumours. MC38-implanted tumours were established by subcutaneously injecting 1 × 10 5 MC38 cells into the right flanks of 6-week-old C57BL/6 female mice (Jackson Laboratory). On the day of tumour cell injection, mice were randomly divided into four groups: control antibody treatment, anti-PD-1 antibody treatment, CDK4/6 inhibitor treatment, and anti-PD-1 antibody plus CDK4/6 inhibitor treatment. Control and anti-PD-1 antibody treatments were conducted by intraperitoneal injection (200 μg per mouse in 200 μl HBSS saline buffer) every three days for a total of 4 injections. The treatment of palbociclib was given by daily oral gavage with the dosage of 200 mg kg −1 for 9 days, with a break after 7 days. Tumours were then collected and single cells were generated from tumour tissues as described above. After cells were filtered through 40-μm strainer, cells were fixed in 0. and implanted in C57BL/6 mice were dissected and photographed after euthanization of mice. l, FACS analysis of the absolute number of CD3 + TILs from 4T1 tumours stably expressing wild-type SPOP or the F102C mutant. n = 5 mice per experimental group. m, B16-F10 tumour cells stably expressing wild-type SPOP or the F102C mutant were implanted into C57BL/6 mice. Tumour-bearing mice were treated with anti-PD-L1 antibody; tumours were then dissected and photographed. n = 7 mice per experimental group. n, The weight of B16-F10 cell derived tumours implanted in C57BL/6 mice that were subsequently treated with anti-PD-L1 antibody. 12 mice per experimental group. o, FACS analysis of relative cell surface expression of PD-L1 in implanted tumours derived from B16-F10 cells expressing wild-type SPOP or the F102C mutant. Animals were treated with anti-PD-L1 antibody. n = 5 mice per experimental group. p, FACS analysis of the absolute number of CD3 + TILs from B16-F10 tumours stably expressing wild-type SPOP or the F102C mutant in mice treated with anti-PD-L1 antibody. n = 7 mice per experimental group. q, B16-F10 cells stably expressing wild-type SPOP or the F102C mutant were inoculated into Tcra −/− mice. After two weeks, tumours were dissected and photographed. n = 7 mice per experimental group. r, Tumour weights of B16-F10 cells stably expressing wild-type SPOP or the F102C mutant and implanted into Tcra −/− mice were dissected and recorded. n = 7 mice per experimental group. s, FACS analysis of relative cell surface expression of PD-L1 from B16-F10 tumours stably expressing wild-type SPOP or the F102C mutant arising in Tcra −/− mice. n = 7 mice per experimental group. Data are mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001, NS, not significant, two-tailed t-test. We determined sample size based on the sufficient statistics. The sample size should be more than 4 across the manuscript. Specifically, for mouse implanted tumor assays, the numbers of mice were included in the figure legends of Fig 2k ; 
Data exclusions
Describe any data exclusions.
No data was excluded from the experiments.
Replication
Describe whether the experimental findings were reliably reproduced.
Yes, the experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Yes, for the xenografted mice assay or mice with palbociclib treatment, mice (from the Jackson Laboratory) were randomized into different groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Yes. The lab technician help to treat mice using the vehicle or CDK4 inhibitor palbociclib. However, to minimize the likelihood of differential treatment or assessments of outcomes during data collection and analysis, animals were pooled and randomly divided into four groups with comparable average tumor size. Moreover, the lab technician who measured the mice were blinded to the treatment groups.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
We used the ImageJ software to quantify the protein bands intensity and used the GraphPad and Excel to do the graph figures and statistics.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restriction.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
All commercial antibodies used in this study were provided with information regarding the dilution, vendor and catalog number (described in the methods/ antibody section). We also used the CRISPR KO or shRNAs to specifically deplete endogenous protein to verify anti-PD-L1, anti-SPOP, anti-Cdh1 and anti-CD8 antibodies. Yes, cell lines used in this study were routinely tested to be negative for mycoplasma.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
N/A
